When major societal upheavals occur, some sectors suffer while others benefit. The COVID-19 pandemic has shifted goalposts for a lot of industries. Most have suffered, but a few, like the mental health industry, have seen an upsurge in demand. The need for mental health products has been rising for decades, but large pharmaceutical companies…
Vancouver, BC – June 16, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy, and pain, is pleased to announce that it has submitted an application to list on The Nasdaq Stock Market (“Nasdaq”). The Company…
Vancouver, British Columbia –June 14, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)(CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced a new appointment to its Board of Directors and one addition to its leadership team: Emer Lahey, Ph.D.,…
Vancouver, BC – June 11, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG)(OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery,will be presenting at the H.C. Wainwright…
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (CSE:DRUG) (OTCQB:BMBIF), a biotechnology company focused on developing novel transformative treatments for neuropsychiatry disorders, epilepsy and pain, today announced that Ian McDonald, Chief Executive Officer, and Dr. Gideon Shapiro Ph.D, Vice President of Discovery, will be presenting…
×
"*" indicates required fields